DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Neutropenia - Pipeline Review, H2 2016" report to their offering.
Neutropenia pipeline therapeutics constitutes close to 26 molecules. Out of which approximately 26 molecules are developed by Companies. Our latest report Neutropenia - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Neutropenia is an abnormally low count of neutrophils, a type of white blood cell that helps fight off infections, particularly those caused by bacteria and fungi. Signs and symptoms include fevers, frequent infections, mouth ulcers, gum infections and dysuria. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 1, 3, 4, 9, 1 and 3 respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects.
Key Topics Covered:
- Introduction
- Neutropenia Overview
- Therapeutics Development
- Pipeline Products for Neutropenia - Overview
- Pipeline Products for Neutropenia - Comparative Analysis
- Neutropenia - Therapeutics under Development by Companies
- Neutropenia - Therapeutics under Investigation by Universities/Institutes
- Neutropenia Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Neutropenia - Products under Development by Companies
- Neutropenia - Products under Investigation by Universities/Institutes
- Neutropenia - Companies Involved in Therapeutics Development
- Apotex Inc.
- BeyondSpring Pharmaceuticals, Inc.
- Biogenomics Limited
- Cellerant Therapeutics, Inc.
- Cleveland BioLabs, Inc.
- Coherus BioSciences, Inc.
- Dr. Reddy's Laboratories Limited
- Eurofarma Laboratorios S.A.
- Ligand Pharmaceuticals, Inc.
- NAL Pharmaceuticals Ltd.
- Prolong Pharmaceuticals, LLC
- Richter Gedeon Nyrt.
- Sandoz International GmbH
- Therapeutic Proteins International, LLC
- Toko Pharmaceutical Industries Co., Ltd.
- USV Pvt Ltd
For more information about this report visit http://www.researchandmarkets.com/research/8w2f8d/neutropenia
